IN THE NEWS
3101, 2017

Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th

Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th PALO ALTO, Calif. – January 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the 19th Annual BIO CEO & Investor Conference at 10:00 am ET on Monday, February 13, 2017, at the Waldorf Astoria Hotel in New York City. A live webcast of the presentation [...]

401, 2017

Eiger Completes $25 Million Debt Financing with Oxford Finance

Eiger Completes $25 Million Debt Financing with Oxford Finance PALO ALTO, Calif., January 4, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that it has completed a $25 million debt financing transaction with Oxford Finance LLC (“Oxford”), a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide.  Proceeds of the financing are intended for use to advance Eiger’s diverse pipeline of clinical stage programs for the treatment of rare diseases, including the Company’s lead program for hepatitis delta virus (HDV) infection, the [...]

301, 2017

Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)

Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH) — First-in-class inhibitor of LTB4 targeting disease modification in PAH PALO ALTO, Calif., January 3, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that the first patient has completed 24 weeks dosing in the double-blind Phase 2 LIBERTY study and has now received treatment with ubenimex in the open-label extension.  LIBERTY is a randomized, double-blind, placebo-controlled study of ubenimex administered orally for a total of 24 weeks in [...]